

ACI-3024

ACI 3024, a small molecule tau inhibitor, ACI-3024, which has demonstrated tau aggregation inhibition in preclinical models is being developed by AC Immune using its proprietary Morphomer™ technology, for the treatment of of Alzheimer's disease.

The Morphomer Tau program discovers small molecules Antidementias, Imaging agents that are designed to inhibit the aggregation and seeding process of misfolded proteins and promote the disaggregation of already formed protein aggregates. Preclinical studies suggest reduction of pathological Tau aggregates leading to memory improvement.

Our two proprietary technology platforms are product focused and highly productive engines for the sustained growth of our Company. Our biological SupraAntigen™ and chemical Morphomer™ platforms are our scientific basis to generate a robust pipeline of antibodies, vaccines and small molecules which selectively bind to misfolded proteins representing the underlying causes of a broad range of neurodegenerative diseases.

Our platforms address two key issues in the development of therapeutics and diagnostics for neurodegenerative diseases:

The body does not make antibodies against misfolded proteins because, although pathogenic, they are still recognized as “self-proteins” and do not trigger an immune response.

The difference between a normal protein and a pathological protein is only related to a conformational change in protein structure making drug specificity difficult to achieve.

SupraAntigen™ platform - Immunotherapy against conformation specific targets

The SupraAntigen™ technology platform was initially developed by our co-scientific founders, Dr. Claude Nicolau in collaboration with Dr. Fred van Leuven to solve the problem of the lack of immunogenicity of “self” proteins. This technology generates conformation specific antibodies and is used to create products for active immunization (vaccines) and passive immunization (antibodies).